RET-IN-21
Based on 1 Customer Validation
RET-IN-21 (compound 5) is a selective RETV804M inhibitor with the IC50 of 0.02 μM. RET-IN-21 does not inhibit the wild type isoforms of RET or KDR. RET-IN-21 has antitumor activity.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 97.02%
- CAS. Nr.: 2414373-42-3
- Formel: C19H16N6O
- Molecular Weight:344.37
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-136534
RET V804M-IN-1RET Inhibitor -
HY-133553
RET-IN-3RET Inhibitor -
HY-110193
SPP-86RET Inhibitor -
HY-18840
BBT594RET Inhibitor -
HY-100459
GSK3179106RET Kinase Inhibitor -
HY-145565
EnbezotinibRET Inhibitor -
HY-114370
SelpercatinibRET Kinase Inhibitor -
HY-112301
PralsetinibRET Inhibitor -
HY-100459R
GSK3179106 (Standard)RET Kinase Inhibitor -
HY-132846
VepafestinibRET Inhibitor -
HY-153175
BT44RET Activator
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BaF3 | IC50 |
4.4 μM
Compound: 5
|
Inhibition of RET V804M mutant (unknown origin)expressed in human BaF3 cells assessed as reduction in cell viability incubated for 48 hrs by celltiter glo luminescence cell viability assay
Inhibition of RET V804M mutant (unknown origin)expressed in human BaF3 cells assessed as reduction in cell viability incubated for 48 hrs by celltiter glo luminescence cell viability assay
|
[PMID: 32292556] |
Chemical Information
-
CAS. Nr. 2414373-42-3
-
Appearance Solid
-
Molecular Weight 344.37
-
Formel C19H16N6O
-
Color Off-white to light yellow
-
SMILES
O=C(N)C1=CC=C(C2=C3N=C(NCC4=CC=NC=C4)C=CN3N=C2)C=C1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 125 mg/mL (362.98 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Reinheit & Dokumentation
-
Data Sheet (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9039 mL | 14.5193 mL | 29.0385 mL | 72.5963 mL |
| 5 mM | 0.5808 mL | 2.9039 mL | 5.8077 mL | 14.5193 mL | |
| 10 mM | 0.2904 mL | 1.4519 mL | 2.9039 mL | 7.2596 mL | |
| 15 mM | 0.1936 mL | 0.9680 mL | 1.9359 mL | 4.8398 mL | |
| 20 mM | 0.1452 mL | 0.7260 mL | 1.4519 mL | 3.6298 mL | |
| 25 mM | 0.1162 mL | 0.5808 mL | 1.1615 mL | 2.9039 mL | |
| 30 mM | 0.0968 mL | 0.4840 mL | 0.9680 mL | 2.4199 mL | |
| 40 mM | 0.0726 mL | 0.3630 mL | 0.7260 mL | 1.8149 mL | |
| 50 mM | 0.0581 mL | 0.2904 mL | 0.5808 mL | 1.4519 mL | |
| 60 mM | 0.0484 mL | 0.2420 mL | 0.4840 mL | 1.2099 mL | |
| 80 mM | 0.0363 mL | 0.1815 mL | 0.3630 mL | 0.9075 mL | |
| 100 mM | 0.0290 mL | 0.1452 mL | 0.2904 mL | 0.7260 mL |
RET-IN-21 Related Classifications
HY-148742 Related Classifications
Powered by Bioz